The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison
Open accessPublished version of a preprint
Abstract
A central paradigm of immunity is that interferon (IFN)-mediated antiviral responses precede pro-inflammatory ones, optimizing host protection and minimizing collateral damage 1,2. Here, we report that for coronavirus disease 2019 (COVID-19) this paradigm does not apply. By investigating temporal IFN and inflammatory cytokine patterns in 32 moderate-to-severe patients with COVID-19 hospitalized for pneumonia and longitudinally followed for the development of respiratory failure and death, we reveal that IFN-λ and type I IFN production were both diminished and delayed, induced only in a fraction of patients as they became critically ill. On the contrary, pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6 and IL-8 were produced before IFNs in all patients and persisted for a prolonged time. This condition was reflected in blood transcriptomes wherein prominent IFN signatures were only seen in critically ill patients who also exhibited augmented inflammation. By comparison, in 16 patients with influenza (flu) hospitalized for pneumonia with similar clinicopathological characteristics to those of COVID-19 and 24 nonhospitalized patients with flu with milder symptoms, IFN-λ and type I IFN were robustly induced earlier, at higher levels and independently of disease severity, whereas pro-inflammatory cytokines were only acutely produced. Notably, higher IFN-λ concentrations in patients with COVID-19 correlated with lower viral load in bronchial aspirates and faster viral clearance and a higher IFN-λ to type I IFN ratio correlated with improved outcome for critically ill patients. Moreover, altered cytokine patterns in patients with COVID-19 correlated with longer hospitalization and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19, contributing to persistent viral presence, hyperinflammation and respiratory failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Impaired and delayed type I and type III IFN responses are associated with risk of severe COVID-19 (Galani et al., 2021; Hadjadj et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Galani et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Cited by
Sorted by citations
Items 301–400 of 504
Mirmohammadi, S., Kianmehr, A., Sabbaghian, A., Mohebbi, A., Shahbazmohammadi, H., Sheykharabi, M., & Bazzi, Z. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105318 · Cited by 7
Shoji, T., Guo, J., Ge, Y., Li, Y., Li, G., Ikezoe, T., Wang, W., Zheng, X., Zhao, S., Fujimura, N., et al. (2022) · Biomolecules · doi:10.3390/biom12101541 · Cited by 7
COVID ‐19 pathophysiology and ultrasound imaging: A multiorgan review
Ito, G. N. W., Rodrigues, V. A. C., Hümmelgen, J., Meschino, G. S. P. G., Abou‐Rejaile, G. M., Brenny, I. D., Júnior, C. R. D. C., Artigas, R. C., Munhoz, J. P. D. S., Cardoso, G. C., et al. (2022) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23160 · Cited by 6
Pesenti, L., Formiga, R. D. O., Tamassia, N., Gardiman, E., de la Héronnière, F. C., Gasperini, S., Chicher, J., Kühn, L., Hammann, P., Gall, M. L., et al. (2025) · Journal of Innate Immunity · doi:10.1159/000543633 · Cited by 6
Payet, L. D., Coléon, A., Bedin, A., Auguste, L., Duroyon, M., Mollévi, C., Blain, H., Mennechet, F. J. D., Jeziorski, É., & Tuaillon, É. (2025) · Scientific Reports · doi:10.1038/s41598-025-13883-7 · Cited by 7
Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19
Liu, Z., Han, Z., Jin, X., An, J., Kim, J., Chen, W., Kim, J. S., Zheng, J., & Deng, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.010 · Cited by 6
Epigenetic repression of antiviral genes by SARS-CoV-2 NSP1
Anastasakis, D. G., Benhalevy, D., Çuburu, N., Altan‐Bonnet, N., & Hafner, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297262 · Cited by 6
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Zheng, H., 中国科学院昆明动物研究所遗传资源与进化国家重点实验室, 生., Song, T., Zheng, Y., & 中国科学院昆明动物研究所模式动物表型与遗传研究国家重大科技基础设施(灵长类设施), 国. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.062 · Cited by 6
Interferon gene expression declines over time post-COVID infection and in long COVID patients
Gómez‐Carballa, A., Pischedda, S., Pardo‐Seco, J., Rial, J. G., Martinón-Torres, F., & Salas, A. (2024) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2024.2389481 · Cited by 6
Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury
Li, Z., Qin, L., Xu, X., Chen, R., Zhang, G., Wang, B., Li, B., & Chu, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561946 · Cited by 6
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath
Chiang, K. C., Rizk, J. G., Nelson, D. J., Krishnamurti, L., Subbian, S., Imig, J. D., Khan, I., Reddy, S. T., & Gupta, A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2031975 · Cited by 6
The effect of age on the magnitude and longevity of Th1‐directed CD4 T‐cell responses to SARS‐CoV ‐2
Nattrass, R. G., Krafft, L., Zjablovskaja, P., Schuster, M., Kasmapour, B., Sarisoy, C., Minich, J., Bach, E., & Streeck, H. (2022) · Immunology · doi:10.1111/imm.13475 · Cited by 4
Hasan, A., Al‐Ozairi, E., Hassan, N. Y., Ali, S., Ahmad, R., Al-Shatti, N., Alshemmari, S., & Al‐Mulla, F. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s360207 · Cited by 6
A survey of mechanisms underlying current and potential COVID‐19 vaccines
Hebel, C., & Thomsen, A. R. (2022) · Apmis · doi:10.1111/apm.13284 · Cited by 6
Smit, W. L., van Tol, S., Haas, L. E. M., Limonard, G. J. M., Bossink, A. W. J., Reusken, C. B. E. M., Heron, M., & Thijsen, S. F. T. (2023) · Virology Journal · doi:10.1186/s12985-023-02050-x · Cited by 6
Zhou, H., Xu, M., Hu, P., Li, Y., Ren, C., Li, M., Yang, P., Wang, S., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172724 · Cited by 6
Potamias, G., Gkoublia, P., & Kanterakis, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1251067 · Cited by 6
Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy
Vajdi, M., Karimi, A., Hassanizadeh, S., Farhangi, M. A., Bagherniya, M., Askari, G., Roufogalis, B. D., Davies, N. M., & Sahebkar, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00585-6 · Cited by 6
Sendo, F., Yoshitake, H., & Araki, Y. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.12978 · Cited by 5
IFNλ: balancing the light and dark side in pulmonary infection
Antos, D., & Alcorn, J. F. (2023) · mBio · doi:10.1128/mbio.02850-22 · Cited by 7
Chen, C., Hsu, M.-K., Huang, Y., Lai, M.-J., Wu, S.-W., Lin, M.-H., Hung, H.-S., Lin, Y.-C., Huang, Y., Lee, Y.-F., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11196 · Cited by 6
Pre-existing interferon gamma conditions the lung to mediate early control of SARS-CoV-2Preprint
Hilligan, K. L., Namasivayam, S., Clancy, C. S., Baker, P. J., Old, S. I., Peluf, V., Amaral, E. P., Oland, S. D., O’Mard, D., Laux, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.15.549135 · Cited by 6
CD55 upregulation in T cells of COVID-19 patients suppresses type-I interferon responses
Detsika, M. G., Σάκκου, Μ., Triantafyllidou, V., Konstantopoulos, D., Grigoriou, E., Psarra, K., Jahaj, E., Dimopoulou, I., Orfanos, S. E., Tsirogianni, A., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08066-z · Cited by 6
Baid, K., Shrivastava, S., Luc, J., Richard, D. J., Aguiar, J. A., Machado, Y. J., Aicher, S., Siwak, K. C., LeBlanc, E. V., Khatooni, Z., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115929 · Cited by 7
Savino, F., Montanari, P., Dini, M., Pau, A., Ferroglio, L., Burdisso, S., Calvi, C., Clemente, A., Gambarino, S., Galliano, I., et al. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113918 · Cited by 5
Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway
Khalil, B. A., Sharif‐Askari, N. S., Hafezi, S., Sharif‐Askari, F. S., Anouti, F. A., Hamid, Q. A., & Halwani, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302818 · Cited by 6
Majewska, M., Maździarz, M. A., Krawczyk, K., Paukszto, Ł., Makowczenko, K. G., Lepiarczyk, E., Lipka, A., Wiszpolska, M., Górska, A., Moczulska, B., et al. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109343 · Cited by 5
Ren, J., Zhang, Z., Xia, Y., Zhao, D., Li, D., & Zhang, S. (2025) · Molecules · doi:10.3390/molecules30020351 · Cited by 6
Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
Wei, X., Rong, N., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993754 · Cited by 6
He, X., Cao, Y., Lu, Y., Qi, F., Wang, H., Liao, X., Xu, G., Yang, B., Ma, J., Li, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181121 · Cited by 5
Pulmonary recovery after COVID-19 – a review
Sonnweber, T., Birgit, S., Weiß, G., & Löffler‐Ragg, J. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2210837 · Cited by 5
Nagaoka, K., Kawasuji, H., Takegoshi, Y., Murai, Y., Kaneda, M., Kimoto, K., Morimoto, S., Tani, H., Niimi, H., Morinaga, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197436 · Cited by 5
Cardiovascular diseases in combination with SARS-CoV-2 viral infection: cours and forecast
Gushchina, O. I., & Ложкина, Н. Г. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-3-97-105 · Cited by 6
Wang, Z., Zhang, Y., Yang, R., Wang, Y., Guo, J., Sun, R., Zhou, Y. M., Li, S., Ge, Q., & Feng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.831194 · Cited by 5
Cytokine profile in community-acquired pneumonia in children
Iziurova, N. V., Savochkina, A. Y., Uzunova, A. N., & Nokhrin, D. Y. (2022) · Medical Immunology (Russia) · doi:10.15789/1563-0625-cpi-2538 · Cited by 5
Genetic Variants and Protective Immunity against SARS-CoV-2
Rabaan, A., Mutair, A. A., Aljeldah, M., Shammari, B. A. A., Sulaiman, T., Alshukairi, A., Alfaresi, M., Al-Jishi, J. M., Bati, N. A. A., Al-Mozaini, M. A., et al. (2022) · Genes · doi:10.3390/genes13122355 · Cited by 4
Multifaceted role of SARS-CoV-2 structural proteins in lung injury
Zheng, G., Qiu, G., Qian, H., Shu, Q., & Xu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332440 · Cited by 6
Kong, X., Wang, Q., Wang, X., Yang, K., Nie, S., Li, Y., Lao, W., Yu, X., Zhang, Y., Li, Z., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02382-2 · Cited by 5
Coagulation and wound repair during COVID-19
Menachery, V. D., & Gralinski, L. E. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.06.006 · Cited by 5
Combining immunomodulators and antivirals for COVID-19
Chen, L. Y. C., & Quach, T. T. T. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00114-2 · Cited by 5
Chong, Z., Karl, C. E., Halfmann, P., Kawaoka, Y., Winkler, E. S., Yu, J., & Diamond, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.21.477296 · Cited by 5
Pegylated Interferon Lambda for Covid-19
Wang, M., Tang, L., & Huang, L. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2303519 · Cited by 5
The seven enigmas of SARS-CoV-2: From the past to the future
Andreakos, E., Arkin, L. M., Bastard, P., Bolze, A., Borghesi, A., Brodin, P., Casanova, J., Casari, G., Cobat, A., Drolet, B. A., et al. (2025) · Journal of Human Immunity · doi:10.70962/jhi.20250149 · Cited by 5
Self-citationZiegler, C. G. K., Owings, A. H., Galeas‐Pena, M., Kazer, S. W., Miao, V. N., Navia, A. W., Tang, Y., Bromley, J. D., Lotfy, P., Sloan, M., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03516-23 · Cited by 6
Divolis, G., Synolaki, E., Tringidou, R., Tzouvelekis, A., Boumpas, D. T., Skendros, P., & Galani, I. E. (2025) · Respiratory Research · doi:10.1186/s12931-025-03180-2 · Cited by 6
Self-citationFerrarese, R., Novazzi, F., Arcari, G., Genoni, A. P., Ferrante, F. D., Clementi, N., Messali, S., Pitrolo, A. M. G., Caccuri, F., Piralla, A., et al. (2025) · Biomolecules · doi:10.3390/biom15111545 · Cited by 4
Revisiting potential value of antitumor drugs in the treatment of COVID-19
Zheng, W., Zeng, Z., Lin, S., & Hou, P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00899-z · Cited by 5
Restrepo‐Vera, J. L., Llauradó, A., Palasí, A., González, V., Gratacos, M., Salvadó, M., Sánchez‐Tejerina, D., Sotoca, J., Raguer, N., & Morales, R. J. (2023) · Acta Neurologica Scandinavica · doi:10.1155/2023/5380946 · Cited by 4
Immunological Facet and Inception after Post-COVID-19 Vaccination
Ray, S. K., & Mukherjee, S. (2023) · Infectious Disorders - Drug Targets · doi:10.2174/1871526523666230406100146 · Cited by 4
Compartmentalized Regulation of Pulmonary and Systemic Inflammation in Critical COVID-19 Patients
Santiago, L., Gonçalves-Pereira, M. H., Vieira, M. S., Ravetti, C. G., Vassallo, P. F., Castro, R. S. E., Pimenta, P. P. C., de Andrade, M. V. M., Santiago, H. C., & Junior, V. A. N. (2023) · Viruses · doi:10.3390/v15081704 · Cited by 4
Patil, S. M., Patil, S., & Gondhali, G. (2023) · South Asian Research Journal of Applied Medical Sciences · doi:10.36346/sarjams.2023.v05i04.005 · Cited by 4
Stem cell-based therapy for COVID-19
Chen, X., Liu, B., Li, C., Wang, Y., Geng, S., Du, X., Weng, J., & Lai, P. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110890 · Cited by 4
Partial remission of advanced untreated Sézary syndrome after COVID-19
Snowden, C. K., Ng, S., & Choi, J. (2022) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.12.005 · Cited by 4
The risk of intrauterine exposure to SARS‐CoV‐2 in female COVID‐19 patients: A comprehensive review
Zhu, G., Liu, L., Huang, X., Li, D., Zhu, Y. Z., Lü, X., & Du, M. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13528 · Cited by 5
Vezzani, B., Neri, M., D’Errico, S., Papi, A. A., Contoli, M., & Giorgi, C. (2022) · Pathogens · doi:10.3390/pathogens11111390 · Cited by 4
Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity
Duette, G., Lee, E., Gomes, G. M. C., Tungatt, K., Doyle, C. M., Stylianou, V. V., Lee, A., Maddocks, S., Taylor, J., Khanna, R., et al. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300034 · Cited by 4
Roche, R., Odeh, N., Andar, A. U., Tulapurkar, M. E., & Roche, J. A. (2023) · Microorganisms · doi:10.3390/microorganisms11081963 · Cited by 4
Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 ScreenPreprint
Kain, A. M., Maarifi, G., Aicher, S., Arhel, N. J., Baidaliuk, A., Munier, S., Donati, F., Vallet, T., Tran, Q. D., Hardy, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.442916 · Cited by 4
Smith, A. P., Williams, E. P., Plunkett, T. R., Selvaraj, M., Lane, L. C., Zalduondo, L., Xue, Y., Vogel, P., Channappanavar, R., Jonsson, C. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.28.482305 · Cited by 4
Sakr, A. A., Mohamed, A. A., Ahmed, A. E., Abdelhaleem, A. A., Samir, H. H., Elkady, M. A., & Hasona, N. A. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29857 · Cited by 3
Tang, S., Takai‐Todaka, R., Ishii, S., Kono, H., Watanabe, R., Ogawa, M., Kano, H., Katayama, K., Sashihara, T., Hojo, K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-17308-3 · Cited by 3
Leberzammer, J., Abplanalp, W. T., Grikscheit, K., Solomonidis, E. G., Glaser, S.-F., Schuhmacher, B., Merten, M., Jeremijev, G., Wilken‐Schmitz, A., Korth, L., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf268 · Cited by 3
Regional immunity in the respiratory tract: challenges and opportunities
Wang, S., Chen, S., Dai, L., Li, F., Li, H., Liu, K., Meng, X., Wang, J., Yue, H., Zhu, A., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.04.057 · Cited by 3
Low Serum Levels of Interferon Alpha in COVID-19 Patients Are Associated with Older Age
Alidjinou, E. K., Hirabidian, M., Rabat, A., Ouafi, M., Nekoua, M. P., Sané, F., Poissy, J., & Hober, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040961 · Cited by 3
Altered anti-viral immune responses in monocytes in overweight heavy drinkers
Kim, A., Ortega‐Ribera, M., McMullen, M. R., Bellar, A., Taiwo, M., Pathak, V., Streem, D. W., Dasarathy, J., Welch, N., Dasarathy, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107133 · Cited by 3
Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19
Woods, E., Mena, A., Sierpinska, S., Carr, E., Bioresource, S., Hagan, R., Crowley, J., Bergin, C. J., Clark, D. M., Brophy, C., et al. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae047 · Cited by 5
Zhang, Y.-W., Han, S., Sun, Q., Liu, T., Wen, Z., Yao, M., Zhang, S., Duan, Q., Zhang, X., Pang, B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460442 · Cited by 3
Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
Österberg, B., Falck‐Jones, S., Vangeti, S., Åhlberg, E., Yu, M., Granja, D., Snik, M. E., Falck‐Jones, R., Barros, G. W. F., Charles, A., et al. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70026 · Cited by 4
Lira‐Junior, R., Ambikan, A. T., Cederholm, A., Rezene, S., Mikaeloff, F., Akusjärvi, S. S., Yalçınkaya, A. S., Chen, X., Sperk, M., Guillen, M. A., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01677-z · Cited by 3
Nguyen, A. N., Kouyate, T. S., Ryff, K., Plotkin, A. L., Doss-Gollin, S., Thomas, S., McEnaney, K., Ozonoff, A., Diray‐Arce, J., Levy, O., et al. (2025) · Journal of Innate Immunity · doi:10.1159/000545432 · Cited by 3
IFN Lambda Deficiency Contributes to Severe COVID-19 Outcomes
Zaleska, A., Dor‐Wojnarowska, A., Radlińska, A., Rorat, M., Szymański, W., Gajewski, A., & Chałubiński, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910530 · Cited by 3
Yan, L., Yuan, C., Zhou, R., Zhong, L., To, K. K., Liu, N., Diao, X., Xie, G., Zhao, H., Hai-jiang, W., et al. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344227 · Cited by 3
Transcriptome Analysis of Lungs in a Mouse Model of Severe COVID-19
Cohen-Gihon, I., Israeli, O., Tidhar, A., Sapoznikov, A., Evgy, Y., Stein, D., Aftalion, M., Gur, D., Orr, I., Zvi, A., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.848465 · Cited by 3
Biological activity of interferons in the novel coronavirus infection COVID-19
Оspelnikova, Т. P., Levitskaya, D. S., Kolodyazhnaya, L. V., Денисовна, Ш. А., Osiptsov, V. N., Arifullina, L., Kryukova, N. O., Пахомов, Д. В., Khromova, E. A., Baranova, I. A., et al. (2022) · Problems of Virology · doi:10.36233/0507-4088-99 · Cited by 4
Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients
Zanetta, C., Rocca, M. A., & Filippi, M. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2064845 · Cited by 3
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
Pelletier, A. N., Sékaly, R., & Tomalka, J. A. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.012 · Cited by 3
Distinct patterns of blood cytokines beyond a cytokine storm predict mortality in COVID-19Preprint
Herr, C., Mang, S., Mozafari, B., Günther, K., Speer, T., Seibert, M., Srikakulam, S. K., Beißwenger, C., Ritzmann, F., Keller, A., et al. (2021) · medRxiv · doi:10.1101/2021.05.04.21256497 · Cited by 3
Pan, T. C., Cao, G.-S., Tang, E.-T., Zhao, Y., Penaloza-MacMaster, P., Fang, Y., & Huang, J. (2022) · bioRxiv · doi:10.1101/2022.01.10.475725 · Cited by 2
Impaired immune response drives age-dependent severity of COVID-19Preprint
Beer, J., Crotta, S., Breithaupt, A., Ohnemus, A., Becker, J., Sachs, B., Kern, L., Llorian, M., Ebert, N., Labroussaa, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.21.489072 · Cited by 3
Zhao, C., Wang, W., Bai, Y., Amonkar, G. M., Mou, H., Olejnik, J., Hume, A. J., Mühlberger, E., Fang, Y., Que, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558606 · Cited by 3
Roméo, P., Conquet, L., Messiaen, S., Pascal, Q., Moreno, S. G., Bravard, A., Bernardino-Sgherri, J., Dereuddre‐Bosquet, N., Montagutelli, X., Grand, R. L., et al. (2024) · Antioxidants · doi:10.3390/antiox13091083 · Cited by 3
Randolph, H. E., Aguirre‐Gamboa, R., Brunet‐Ratnasingham, E., Nakanishi, T., Mu, Z., Locher, V., Ketter, E., Brandolino, C., Larochelle, C., Prat, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72393-w · Cited by 2
Biological Plausibility Between Long-COVID and Periodontal Disease Development or Progression
Andriankaja, O. M., Whiteheart, S. W., & Mattos, M. B. D. A. (2025) · Biomedicines · doi:10.3390/biomedicines13123023 · Cited by 2
A rare case of SARS-CoV-2 and influenza A virus super-infection
Arcangeletti, M. C., Conto, F. D., Montecchini, S., Buttrini, M., Maccari, C., Chezzi, C., & Calderaro, A. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115743 · Cited by 2
A Game of Infection – Song of Respiratory Viruses and Interferons
Wang, G., Gu, Y., Wang, C., Wang, F., & Hsu, A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.937460 · Cited by 2
Importance of screening severe COVID-19 patients for IFN-λ1, IL-6 and anti-S1 IgG levels
Kenanoğlu, O. B., Gül, A., Can, H., Karakavuk, M., Alak, S. E., Korukluoğlu, G., Altaş, A. B., Pullukçu, H., Döşkaya, A. D., Karakavuk, T., et al. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156357 · Cited by 2
Modeling the transmission dynamics of COVID-19 with genetically resistant humans
Onifade, A. A., Idisi, I. O., & Kareem, L. A. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02240 · Cited by 2
IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19
Paikar, S., Bahrami, N., Tabatabai, R. R., & Mohamadnia, A. (2024) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-144812 · Cited by 2
Aqillouch, S., Zerrad, C., Laazaazia, O., Ouladlahsen, A., Bissati, K. E., Akarid, K., Pineau, P., Benjelloun, S., & Ezzikouri, S. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111149 · Cited by 2
Marin, D., Fernández, G. J., Hernández, J. C., & Taborda, N. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314754 · Cited by 2
Rouzé, A., Póvoa, P. M. S. R., Martín‐Loeches, I., Saura, O., Maizel, J., Pouly, O., Makris, D. A., du Cheyron, D., Tamion, F., Labruyère, M., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03148-2 · Cited by 2
Hashemian, S. M., Jafari, A., Khoundabi, B., Jamaati, H., & Rahimi, P. (2025) · Health Science Reports · doi:10.1002/hsr2.70571 · Cited by 3
Anžič, N., Stoiber, W., Obermeyer, A., Mertz, K. D., Stalder, A. K., Haslbauer, J. D., & Tzankov, A. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf056 · Cited by 2
IMMUNOLOGICAL RESPONSE TO SARS-COV 2 AND IMMUNOPATHOLOGY OF COVID-19 INFECTION
Abdul-Rahman, G. Y., & Mohammed, G. (2022) · MINAR International Journal of Applied Sciences and Technology · doi:10.47832/2717-8234.11.4 · Cited by 2
Haberland, A., & Müller, J. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13954 · Cited by 1
SEVERE CORONAVIRUS DISEASE 2019: FROM PATHOGENESIS TO THERAPY
Cavaillon, J., Artigas, A., Barratt‐Due, A., Giamarellos‐Bourboulis, E. J., Gómez, H., Hayem, G., Vlaar, A. P. J., & Wiersinga, W. J. (2022) · Shock · doi:10.1097/shk.0000000000001956 · Cited by 2
Han, Y., Bai, X., Wu, S., Luan, X., Ren, L., Wang, J., She, Z., Xiao, B., & Du, G. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/9955105 · Cited by 2
Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2
Opsteen, S., Fram, T., Files, J. K., Levitan, E. B., Goepfert, P., & Erdmann, N. B. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003399 · Cited by 2
Bakasis, A., & Moutsopoulos, H. Μ. (2021) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.32.3.188 · Cited by 2
Ziegler, C. G. K., Owings, A. H., Miao, V. N., Navia, A. W., Tang, Y., Bromley, J. D., Lotfy, P., Sloan, M., Laird, H., Williams, H. B., et al. (2022) · medRxiv · doi:10.1101/2022.10.25.22281528 · Cited by 2
Metadata
- Authors
- Galani, I.-E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P. C., Panou, V., Rapti, V., Koltsida, O., Mentis, A., Koulouris, N., Tsiodras, S., Koutsoukou, A., & Andreakos, E.
- Affiliations
- Biomedical Research Foundation of the Academy of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Sotiria General Hospital (GR)
- Pasteur Hellenic Institute (GR)
- Corresponding author
- Andreakos, Evangelos
- ORCID
- Venue
- Nature Immunology
- Published
- 2020-12-04
- Volume
- 22
- Issue
- 1
- Pages
- 32-40
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W3107596380
- Cited by
- 503
- References
- 41
- Citations by year
- 2026: 22 · 2025: 46 · 2024: 58 · 2023: 91 · 2022: 156 · 2021: 128 · 2020: 1
- FWCI
- 32.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Immunology (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- EC | Horizon 2020 Framework Programme (779295, 767015)
- Janssen Pharmaceuticals
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, SARS-CoV-2, influenza, type I interferon, interferon lambda, antiviral immunity, inflammatory cytokines, interleukin-6, TNF-α, interleukin-8, hyperinflammation, viral load, viral clearance, respiratory failure, mortality, blood transcriptome, cytokine dynamics
- MeSH terms
- COVID-19, SARS-CoV-2, Interferon Lambda, Humans, Immunity, Inflammation, Influenza, Human, Interferon Type I, Interferons, Length of Stay, Prognosis, Gene Expression, Cytokines, Disease Progression, Viral Load, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
